NUFORMIX PLC

AGM Information • Aug 24, 2023

National Storage Mechanism | Additional information

RNS Number : 3775K

Nuformix PLC

24 August 2023

Nuformix plc

("Nuformix" or the "Company")

Result of Annual General Meeting

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing,  announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved on a show of hands at the meeting. 

The results of the proxies appointing the Chair of the meeting are reported below:

	Resolution	Ordinary/ Special	For		Against		Total votes cast
			No. of votes	%	No. of votes	%
1	To re-appoint Daniel Gooding as a director	Ordinary	94,720,614	99.67	312,357	0.33%	95,032,971
2	To re-appoint Julian Gilbert as a director	Ordinary	94,720,614	99.67	312,357	0.33%	95,032,971
3	To re-appoint s Madeleine Kennedy as a director	Ordinary	92,448,034	99.66	312,357	0.34%	92,760,391
4	To authorise the Directors to allot shares.	Ordinary	92,082,014	96.19	3,652,015	3.81%	95,734,029
5	To authorise the Directors to disapply pre-emption rights.	Special	92,082,014	98.52	1,379,435	1.48%	93,461,449
6	To authorise the Company to purchase its own shares.	Special	92,306,372	96.32	3,527,841	3.68%	95,834,213
7	To authorise calling of a general meeting on 14 clear days' notice.	Special	93,093,402	97.14	2,740,811	2.86%	95,834,213

A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.

The Company's issued share capital is 744,309,368 ordinary shares of £0.001 each.

Enquiries:

Nuformix plc
Dr Daniel Gooding, Executive Director Dr Julian Gilbert, Non-executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	+44 (0) 20 3650 3650
John Howes (Corporate Broking)	+44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe Zach Cohen	+44 (0) 20 3934 6630 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFFFTLISFIV